Oncology research and treatment · 2026
Dose-Dependent Intracranial Response to Sotorasib in KRASG12C-Mutated Lung Cancer Brain Metastases: A Case Report.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hoersting Niklas, Hense Joerg, Schuler Martin, Guberina Nika, Guberina Maja, Opitz Marcel, Wiesweg Marcel
Аннотация
INTRODUCTION: KRASG12C inhibitors such as sotorasib have expanded precision-oncology options for non-small cell lung cancer (NSCLC). However, central nervous system (CNS) disease control remains a major clinical challenge.
CASE PRESENTATION: We report the case of a female patient with extensively pretreated KRASG12C-mutated lung adenocarcinoma and metachronous progressive brain metastases. Initially, peripheral and cerebral lesions responded to once daily sotorasib 960 mg (standard dose). Following cerebral progression, tolerance-adapted escalation to 1,920 mg achieved renewed intracranial disease control.
CONCLUSION: In conclusion, this case illustrates that tolerance-adapted dose escalation may offer a meaningful therapeutic option for selected patients experiencing CNS progression under standard dosing.
CASE PRESENTATION: We report the case of a female patient with extensively pretreated KRASG12C-mutated lung adenocarcinoma and metachronous progressive brain metastases. Initially, peripheral and cerebral lesions responded to once daily sotorasib 960 mg (standard dose). Following cerebral progression, tolerance-adapted escalation to 1,920 mg achieved renewed intracranial disease control.
CONCLUSION: In conclusion, this case illustrates that tolerance-adapted dose escalation may offer a meaningful therapeutic option for selected patients experiencing CNS progression under standard dosing.